Orthocell has been featured in The Market Herald, following our announcement of patents granted in Canada and Hong Kong for CelGro.
Video | Proactive Investors – September 2021
Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about passing a key milestone in the OrthoATI™ rotator cuff tendon study.
Orthocell’s (ASX:OCC) final patient completes treatment in tendon regeneration study
Orthocell has been featured in The Market Herald, highlighting the follow-up announcement from our OrthoATI™ rotator cuff tendon regeneration study.
Video | Proactive Investors – Orthocell highlights potential for CelGro in treatment of lymphedema
Orthocell CEO and Managing Director Paul Anderson speaks to Proactive after announcing a breakthrough tissue engineering study, combining CelGro™ with lymphatic and blood vessel cells to create functional lymphatic tissue, has been published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Orthocell (ASX:OCC) has breakthrough tissue engineering study published in US
Orthocell has been featured in The Market Herald, following the publication of our breakthrough tissue engineering study in the peer-reviewed journal “Proceedings of the National Academy of Sciences of the United States of America”.
Orthocell (ASX:OCC) appoints exclusive distributor for Striate+
Orthocell has been featured in The Market Herald, announcing the appointment of Samson Medical Technologies (SMT) as its exclusive distributor for Striate+ across Australia.
Video | Stockhead Investor Presentation – June 2021
Orthocell CEO and Managing Director Paul Anderson spoke with Oriel Morrison as part of Stockhead V-Con Biotechs.
Video | Ticker News Interview – June 2021
Orthocell CEO and Managing Director, Paul Anderson, spoke with Ticker News about the positive findings from our CelGro™ clinical study.
Video | Proactive Investors – June 2021
Orthocell CEO and Managing Director Paul Anderson discusses with Proactive positive nerve regeneration results one year on from a study testing its nerve repair candidate on quadriplegic patients.
Orthocell (ASX:OCC) demonstrates potential to return function to paralysed limbs
Orthocell has been featured in The Market Herald, following the announcement of clinical data from the CelGro nerve regeneration trial demonstrating the potential to return function to paralysed upper limbs following 12 months of treatment
Read the article HERE.